The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants further shift the complicated treatment algorithm. Roche / Genentech’s Ocrevus, Merck Serono’s Mavenclad, and a growing array of next-generation compounds from Novartis, Celgene, Actelion/Janssen, Biogen, Genmab, and TG Therapeutics will intensify competition in the saturated relapsing MS market. Meanwhile, Ocrevus continues to transform treatment in the
- What is the commercial outlook for Ocrevus, Mavenclad, next-generation
fumarates, and S1P receptor modulators in the competitive relapsing MS space, and where will they fit into an evolving treatment algorithm?
- What impact will Ocrevus and
ibudilasthave in the progressive MS market?
- What clinical roles will
entrenchedplatform injectables, current and next-generation orals, and MAbsplay in the evolving MS treatment algorithm?
- How will generic competition shape the MS market?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other DRG research.
Epidemiology: Diagnosed prevalence of MS by country, segmented by CIS, RR-MS, SP-MS, and PP-MS; drug-treated cases.
Emerging therapies: Phase II: 9 drugs; Phase III/preregistration: 10 drugs; coverage of select Phase I products.
Market forecast features: Patient-based market forecast extending through 2028, segmented by brands/generics.
Disease Landscape & Forecast provides